Background And Aims: To determine the cost-effectiveness of anti-obesity medications (AOM): tirzepatide, semaglutide, liraglutide, phentermine plus topiramate (PpT), and naltrexone plus bupropion (NpB).
Methods And Results: From a U.S. perspective we developed a Markov model to simulate weight change over a 40-year time horizon using results from clinical studies. According to the body mass index (BMI), cardiovascular diseases, diabetes and mortality risk were the health states considered in the model, being mutually exclusive. Costs of AOM, adverse events, cardiovascular events, and diabetes were included. We applied a 3% per-year discount rate and calculated the incremental cost-effectiveness ratios (ICERs) of cost per quality-adjusted life-year (QALY) gained. Probabilistic sensitivity analyses incorporated uncertainty in input parameters. A deterministic analysis was conducted to determine the robustness of the model. The model included a cohort of 78.2% females with a mean age of 45 years and BMI of 37.1 (SD 4.9) for females and 36.8 (SD 4.9) for males. NpB and PpT were the least costly medications and, all medications differed no more than 0.5 QALYs. Tirzepatide ICER was $355,616 per QALY. Liraglutide and semaglutide options were dominated by PpT.
Conclusion: Compared to other AOM, PpT was lowest cost treatment with nearly identical QALYs with other agents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.numecd.2023.03.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Insulinotropic and anti-obesity properties of ethno-medicinal plants: pharmacology-based and predictions.
Nat Prod Res
January 2025
Department of Pharmacognosy and Medicinal Plants, Faculty of Pharmacy, Al-Azhar University (Boys), Cairo, Egypt.
The herbal extracts of four traditional plants; namely leaves, fruits leaves, and seeds, were identified for their main constituents using UHPLC/QTOF-MS/MS. Then, a pharmacology-based analysis and molecular docking verification were established targeting the evaluation of each individual herbal extract for their antidiabetic/anti-obesity potential besides their safety. Streptozotocin-induced diabetic rats were used to evaluate antiobesity and insulinotropic effects against insulin (10 U/Kg, IP) and metformin (100 mg/Kg, per oral) as standard regimens.
View Article and Find Full Text PDFPotential therapeutic strategies for MASH: from preclinical to clinical development.
Life Metab
October 2024
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Current treatment paradigms for metabolic dysfunction-associated steatohepatitis (MASH) are based primarily on dietary restrictions and the use of existing drugs, including anti-diabetic and anti-obesity medications. Given the limited number of approved drugs specifically for MASH, recent efforts have focused on promising strategies that specifically target hepatic lipid metabolism, inflammation, fibrosis, or a combination of these processes. In this review, we examined the pathophysiology underlying the development of MASH in relation to recent advances in effective MASH therapy.
View Article and Find Full Text PDFExperiences and overall impact reported by people living with obesity: results from a multinational study.
SAGE Open Med
January 2025
Endocrinology Diabetes, Metabolism, and Obesity Medicine, Obesity, Endocrine, and Metabolism Center (OEMC), King Fahad Medical City (KFMC), Riyadh, Saudi Arabia.
Objectives: To explore the impact of obesity on clinical outcomes, health-related quality of life, emotional well-being, and work productivity in people/patients with obesity across six countries by body mass index and the presence of complications.
Methods: Adelphi Real World Obesity Disease Specific Programme™ captured data related to physicians and their consulting people/patients with obesity on a weight management program or anti-obesity medication in Brazil, Canada, China, Japan, Kingdom of Saudi Arabia, and the United Arab Emirates from April to December 2022. Physicians reported data for up to eight qualifying people/patients with obesity.
Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP.
Adv Sci (Weinh)
January 2025
Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, 30322, USA.
Triple-negative breast cancer (TNBC) in obese patients remains challenging. Recent studies have linked obesity to an increased risk of TNBC and malignancies. Through multiomic analysis and experimental validation, a dysfunctional Eukaryotic Translation Initiation Factor 3 Subunit H (EIF3H)/Yes-associated protein (YAP) proteolytic axis is identified as a pivotal junction mediating the interplay between cancer-associated adipocytes and the response to anti-cancer drugs in TNBC.
View Article and Find Full Text PDFThe use of an automatic remote weight management system to track treatment response, identified drugs supply shortage and its consequences: A pilot study.
Digit Health
January 2025
Ohad Cohen Endocrinology, Tel Hashomer, Israel.
Objective: The objective of this pilot study is to evaluate the feasibility of using an automatic weight management system to follow patients' response to weight reduction medications and to identify early deviations from weight trajectories.
Methods: The pilot study involved 11 participants using Semaglutide for weight management, monitored over a 12-month period. A cloud-based, Wi-Fi-enabled remote weight management system collected and analyzed daily weight data from smart scales.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!